What happened
Daewoong Pharma filed provisional (unaudited) separate results for Q4 2025: revenue of US$243M (+8.7% year on year), operating profit of US$31.1M (+8.97% year on year) and net income of US$30.4M (from a loss a year earlier).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$243M |
|---|---|
| Revenue vs a year earlier | +8.7% |
| Operating profit | US$31.1M |
| Net income | US$30.4M |
| Period | Q4 2025 (separate) |
| Filed | 2026-02-09, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260209800757 → open original filing |
Source: DART. Information only, not investment advice.